American Society of Hematology. (2019).
FDA Approves Crizanlizumab-tmca for Sickle Cell Disease.
Retrieved from https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/fda-approves-crizanlizumab-tmca-for-sickle-cell-disease.
American Society of Hematology.
"FDA Approves Crizanlizumab-tmca for Sickle Cell Disease." Hematology.org.
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/fda-approves-crizanlizumab-tmca-for-sickle-cell-disease
(label-accessed April 20, 2024).
"American Society of Hematology."
FDA Approves Crizanlizumab-tmca for Sickle Cell Disease, 20 Apr. 2024 ,
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/fda-approves-crizanlizumab-tmca-for-sickle-cell-disease.
